KOL Identification

A major diagnostics manufacturer had developed a novel technology for the rapid detection of infectious pathogens and required assistance in developing commercialization strategy and sales tactics. DeciBio’s services were contracted to profile relevant stakeholders, characterize existing workflows and acquisition / implementation processes, and develop a product-specific launch strategy.

A leader in synthetic oligonucleotide manufacturing wanted to assess the total market size and opportunity

A group asked DeciBio to identify and evaluate clinical genetic testing labs for potential acquisition

A leading diagnostics player asked DeciBio to characterize the evolving NIPT market to help inform strategic positioning regarding menu offerings and technological approach

A top-10 scientific service provider wanted to quantify the size of the CGT services market and understand trends within

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally